Rotenone Directly Induces BV2 Cell Activation via the p38 MAPK Pathway

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Gao, Feng ^a   Chen, Dong ^b   Hu, Qingsong ^b   Wang, Guanghui ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P10; REACTIVE OXYGEN METABOLITE; ROTENONE;

ANIMAL CELL; ANTIBODY DETECTION; ARTICLE; CELL ACTIVATION; CELL FRACTIONATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; ENZYME ACTIVATION; IMMUNOBLOTTING; MICROGLIA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; CELL LINE; CELL NUCLEUS; ENVIRONMENTAL POLLUTANTS; HUMANS; I-KAPPA B KINASE; INFLAMMASOMES; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; MICE; MICROGLIA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; ROTENONE; TRANSCRIPTION FACTOR RELA;

EID: 84882643371     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072046     Document Type: Article

References (31)

1. Dawson TM, Dawson VL, (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302: 819-822.
2. England AC, Jr., Schwab RS (1998) Parkinson's syndrome. N Engl J Med 265: 837-844 concl.
3. Abou-Sleiman PM, Muqit MM, Wood NW, (2006) Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7: 207-219.
4. Dauer W, Przedborski S, (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909.
5. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, et al. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306.
6. Schapira AH, (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7: 97-109.
7. Hirsch EC, Hunot S, (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8: 382-397.
8. Lucin KM, Wyss-Coray T, (2009) Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64: 110-122.
9. Miller RL, James-Kracke M, Sun GY, Sun AY, (2009) Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 34: 55-65.
10. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, et al. (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57: 168-175.
11. Block ML, Hong JS, (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76: 77-98.
12. Phani S, Loike JD, Przedborski S, (2012) Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord 18Suppl 1: S207-209.
13. Gao HM, Hong JS, (2008) Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 29: 357-365.
14. Vroon A, Drukarch B, Bol JG, Cras P, Breve JJ, et al. (2007) Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. Exp Gerontol 42: 762-771.
15. Zhou F, Wu JY, Sun XL, Yao HH, Ding JH, et al. (2007) Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology 32: 2570-2580.
16. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH, (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.
17. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, et al. (2009) A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137: 47-59.
18. Manthripragada AD, Schernhammer ES, Qiu J, Friis S, Wermuth L, et al. (2011) Non-steroidal anti-inflammatory drug use and the risk of Parkinson's disease. Neuroepidemiology 36: 155-161.
19. Qin L, Wu X, Block ML, Liu Y, Breese GR, et al. (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 453-462.
20. Gao HM, Liu B, Zhang W, Hong JS, (2003) Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J 17: 1957-1959.
21. Wada R, Tifft CJ, Proia RL, (2000) Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci U S A 97: 10954-10959.
22. Hu Q, Li B, Xu R, Chen D, Mu C, et al. (2012) The protease Omi cleaves the mitogen-activated protein kinase kinase MEK1 to inhibit microglial activation. Sci Signal 5: ra61.
23. Tian LP, Zhang S, Xu L, Li W, Wang Y, et al. (2012) Selenite benefits embryonic stem cells therapy in Parkinson's disease. Curr Mol Med 12: 1005-1014.
24. Tak PP, Firestein GS, (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107: 7-11.
25. Skaug B, Jiang X, Chen ZJ, (2009) The role of ubiquitin in NF-kappaB regulatory pathways. Annu Rev Biochem 78: 769-796.
26. Gilmore TD, (2006) Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25: 6680-6684.
27. Schroder K, Tschopp J, (2010) The inflammasomes. Cell 140: 821-832.
28. Hayden MS, Ghosh S, (2008) Shared principles in NF-kappaB signaling. Cell 132: 344-362.
29. Kuwahara I, Lillehoj EP, Lu W, Singh IS, Isohama Y, et al. (2006) Neutrophil elastase induces IL-8 gene transcription and protein release through p38/NF-{kappa}B activation via EGFR transactivation in a lung epithelial cell line. Am J Physiol Lung Cell Mol Physiol 291: L407-416.
30. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, et al. (2001) ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2: 222-228.
31. Matsuzawa A, Saegusa K, Noguchi T, Sadamitsu C, Nishitoh H, et al. (2005) ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol 6: 587-592.